Cheryl Lee, MD, considers the updates on several studies presented at ASCO 2022, which, though not immediately practice-changing, offer encouraging glimpses of prospective bladder cancer treatments. Starting with a look at a report on the BAYOU study, Dr Lee notes how results of this trial, though not indicating significant therapeutic differences between the involved regimens, point to potential treatments for a subgroup of patients, those with DNA repair alterations.
Dr Lee also reviews the neoadjuvant setting, specifically a study on enfortumab vedotin (EV) as monotherapy for muscle-invasive disease that produced not only an impressive complete pathologic response, but also an equally impressive pathologic downstaging. Positive long-term data about EV are also mentioned, prompting an optimism regarding this antibody-drug conjugate as a treatment for locally advanced and metastatic bladder cancer, and, more generally, a solid sense of a base of research "to build on."
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: ASCO 2022: A Reflection on Data to Build On in Bladder Cancer - Medscape - Jun 30, 2022.